208 related articles for article (PubMed ID: 30489037)
1. Adjuvant therapy after nephrectomy for renal cell carcinoma.
Ravaud A
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():33-36. PubMed ID: 30489037
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one.
Ravaud A
Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():12-17. PubMed ID: 32852898
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.
Bandini M; Smith A; Marchioni M; Pompe RS; Martel TF; Cindolo L; Montorsi F; Shariat SF; Briganti A; Kapoor A; Capitanio U; Karakiewicz PI
Clin Genitourin Cancer; 2018 Jun; 16(3):176-183. PubMed ID: 29449091
[TBL] [Abstract][Full Text] [Related]
5. Association between age and sex and mortality after adjuvant therapy for renal cancer.
Mamtani R; Wang XV; Gyawali B; DiPaola RS; Epperson CN; Haas NB; Dutcher JP
Cancer; 2019 May; 125(10):1637-1644. PubMed ID: 30620389
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Ravaud A; Motzer RJ; Pandha HS; George DJ; Pantuck AJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Martini JF; Ramaswamy K; Casey M; Staehler M; Patard JJ;
N Engl J Med; 2016 Dec; 375(23):2246-2254. PubMed ID: 27718781
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
[TBL] [Abstract][Full Text] [Related]
8. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
Ristau BT; Manola J; Haas NB; Heng DYC; Messing EM; Wood CG; Kane CJ; DiPaola RS; Uzzo RG
J Urol; 2018 Jan; 199(1):53-59. PubMed ID: 28728992
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
[TBL] [Abstract][Full Text] [Related]
11. [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
Rexer H
Urologe A; 2011 Apr; 50(4):489-92. PubMed ID: 21472622
[No Abstract] [Full Text] [Related]
12. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.
Kim SP; Crispen PL; Thompson RH; Weight CJ; Boorjian SA; Costello BA; Lohse CM; Leibovich BC
Cancer; 2012 Sep; 118(18):4412-20. PubMed ID: 22952032
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
14. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
16. The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis.
Kourie HR; Bakouny Z; Eid R; Haddad FG; Kattan J
Future Oncol; 2018 Apr; 14(9):829-835. PubMed ID: 29589470
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
18. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
Gyawali B; Ando Y
Ann Oncol; 2017 Apr; 28(4):898-899. PubMed ID: 27993814
[No Abstract] [Full Text] [Related]
20. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
